-
Mashup Score: 0
, Department of Medicine and Surgery, , University of Insubria, , Varese, , Italy,, Department of Internal Medicine, , University of Virginia, , Charlottesville, , VA,, Department of Kinesiology and Health Sciences, College of Humanities and Sciences, , Virginia Commonwealth University, , Richmond, , VA,, Department of Kinesiology and Health Sciences, College of Humanities and Sciences, , Virginia Commonwealth University, , Richmond, , VA,, Department of Cardiovascular Medicine, , Fondazione Policlinico
Source: www.ahajournals.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Response to Interleukin-1 Blockade With Anakinra in Black and White Americans With ST-Segment Elevation Myocardial Infarction - 1 year(s) ago
Author links open overlay panel Giuliana Corna MD a b, Michele Golino MD a c, Francesco Moroni MD d e, Marco Giuseppe Del Buono MD f, Azita H. Talasaz PharmD, PhD g, Santiago Decotto MD a h, James Mbualungu BS i, Cory R. Trankle MD a, Georgia K. Thomas MD, PhD a, Roshanak Markley MD a, Justin M. Canada PhD a, Jeremy Turlington MD a, Carla R. Agatiello MD b, Larry Keen PhD j, Benjamin Van Tassell PharmD a g, Antonio Abbate MD, PhD
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet-
RT @GiulianaCorna: Response to Anakinra in Black and White Americans with STEMI🫀 🔗 https://t.co/8HRAfwh7Nj @AbbateAntonio @bvantassell @m…
-
-
Mashup Score: 1Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution? - 2 year(s) ago
This editorial refers to ‘The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the M
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
RT @AbbateAntonio: @kaulcsmc @gbiondizoccai @MarcoDelBuono3 @jgchiabrando1 @bvantassell https://t.co/28E3psSYMK - recommend reading accompa…
-
-
Mashup Score: 0
AbstractAims. Acute coronary syndromes (ACSs) are driven by inflammation within coronary plaque. Interleukin-1 (IL-1) has an established role in atherogenesis a
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
@gbiondizoccai @MarcoDelBuono3 @jgchiabrando1 @bvantassell @AbbateAntonio Reduced inflammatory markers in MRC-ILA Heart Study (NSTE-ACS), but excess MACE events at 1yr with Anakinra (13 vs 4). https://t.co/YYWsB75fmy
-
-
Mashup Score: 0Clinical and Pharmacological Implications of Time to Treatment with Interleukin-1 Blockade in ST-Segment Elevation Myocardial Infarction - 2 year(s) ago
Interleukin-1 (IL-1) blockade with anakinra given within 12 hours from reperfusion has been shown to reduce the inflammatory response as well as prevent heart failure (HF) events in patients with STEMI.We sought to determine whether time-to-treatment influences the efficacy of anakinra on systemic inflammation and incidence of HF events in patients with STEMI . We divided the cohort in two groups…
Categories: Cardiologists, Latest HeadlinesTweet-
Clinical and Pharmacological Implications of Time to Treatment with Interleukin-1 Blockade in ST-Segment Elevation Myocardial Infarction, by Del Buono et al https://t.co/mtCSaoGlNv @MarcoDelBuono3 @jgchiabrando1 @bvantassell @AbbateAntonio https://t.co/TShe1Duc3w
-
-
Mashup Score: 4
Background Heart failure (HF) is a global leading cause of mortality despite implementation of guideline directed therapy which warrants a need for novel treatment strategies. Proof-of-concept clinical trials of anakinra, a recombinant human Interleukin-1 (IL-1) receptor antagonist, have shown promising results in patients with HF. Method We designed a single center, randomized, placebo…
Source: BioMed CentralCategories: Cardiologists, Latest HeadlinesTweet-
Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): randomized, double blind, placebo controlled, single center, phase 2 study, by Van Tassell et al https://t.co/hdgkvP64rV @bvantassell @DaveDixonPharmD @MarcoDelBuono3 @AbbateAntonio https://t.co/5daQ9IYhT0
-
-
Mashup Score: 0Wolters Kluwer Health - 3 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: lww.comCategories: Cardiologists, Latest HeadlinesTweet-
Effect of IL-1 Blockade with Anakinra on Heart Failure Outcomes in Patients with Anterior versus Non-Anterior STEMI, by Del Buono et al https://t.co/eV32GllaBW @JCVPOnline @MarcoDelBuono3 @jgchiabrando1 @CoryRTrankle @bvantassell @AbbateAntonio https://t.co/pLABlGsWmW
-
-
Mashup Score: 0
Leukocytosis is a common finding in patients with ST elevation myocardial infarction (STEMI) and portends a poor prognosis. Interleukin 1-β regulates leukopoiesis and pre-clinical studies suggest that anakinra (recombinant human interleukin-1 [IL-1] receptor antagonist) suppresses leukocytosis in myocardial infarction. However, the effect of IL-1 blockade with anakinra on leukocyte count in…
Source: NatureCategories: Cardiologists, Latest HeadlinesTweet-
Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction, by Del Buono et al https://t.co/W227kwZijB @MarcoDelBuono3 @CoryRTrankle @totocarbone @bvantassell @AbbateAntonio https://t.co/QXxZZRtYIj
-
-
Mashup Score: 2Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review - 3 year(s) ago
Abstract Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patie…
Categories: Cardiologists, Latest HeadlinesTweet-
Congrats @VCUPharmacy @VCUHealthHeart @DaveDixonPharmD @bvantassell on a well written review on the use of lipid lowering therapy for the management of #COVID19 @AbbateAntonio @virani_md https://t.co/pO5H2STTIK
-
-
Mashup Score: 7Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension: - 4 year(s) ago
Abstract Background Standard blood pressure control metrics may not account for fluctuations in blood pressure over time. Objectives This study sought to estimate the independent association betwee…
Categories: Cardiology News and Journals, Latest HeadlinesTweet-
Editors’ Insights: New research suggests time in therapeutic range for #hypertension predicts #CV outcomes and is perhaps a better measure than mean blood pressure. Do you agree? https://t.co/MS83WMveIe @lfbpharmd @DaveDixonPharmD @bvantassell #JACC #bloodpressure #CardioTwitter https://t.co/1ks49gxYt4
-
Patients with HFpEF show a differential response to IL-1 blockade, with those with LVEF ≥ 60% having a greater improvement in peak VO2. #AHAJournals #ResearchLetter @AbbateAntonio @bvantassell @micheleg1390 @FrnMoroniMD @UVACVRC @CardioUVA @VCUHealthHeart https://t.co/FlfBJV43y8